Chronic Pain Clinical Trial
Official title:
Transcranial Direct Current Stimulation Associated With Peripheral Electrical Stimulation for Pain Control in Individuals With Sickle Cell Disease
So far, no study investigated the safety and efficacy analgesic of transcranial direct current stimulation (tDCS) associated to peripheral electrical stimulation (PES) in individuals with SCD who suffer from chronic pain. Several studies have reported a decrease in O²Hb concentration in the regions below the electrodes and in other cortical areas during anodic or cathodic tDCS, which implies a risk factor for vasoocclusive events in individuals with SDC due to polymerization of hemoglobin when exposed to these low O²Hb concentrations. For this reasion, the aim main of this study is to assess the effect of a single session of transcranial direct current stimulation (tDCS) associated to peripheral electrical stimulation (PES) on safety and efficacy analgesic in individuals with sickle cell disease (SCD). Others aims sencondaries are evaluate the effect of a single session of transcranial direct current stimulation (tDCS) associated to peripheral electrical stimulation (PES) on biomarkers neurophysiological and inflammatory.
Pain, in its various manifestations, is the symptom most often associated to SCD, being
responsible for over 90% of hospital admissions. Oftenly pain has a major impact on the
patient's life and is associated with some degree of disability. Chronic pain may reflect the
continuity of tissue injury and central nervous system maladaptive plasticity. They start
with tissue injuries such as leg ulcers, avascular osteonecrosis, chronic osteomyelitis,
arthropathy, or even continue after the repair process, by central nervous sensitization and
/ or peripheral. The lack of diagnosis in cases of chronic and neuropathic pain in patients
with SCD is common, implying inappropriate use of therapeutic resources by the health
services, resulting in increased suffering to the patient. The release of inflammatory
mediators is related to the perception of pain, and may cause nociceptor sensitization.
The tDCS has the potential to change the neuronal membrane resting potential, this effect is
dependent on the polarity, being that cathode produces hyperpolarization, whereas anode
produces depolarization, in this way can induce an effect of inhibition and facilitation of
neuronal firing, respectively. This effects can induces changes in cortical excitability.
Although tDCS may modulate areas related to endogenous pain control, its effects seem to be
diffuse, and focality would probably enhance its effects. The peripheral electrical
stimulation (PES), in another way, may also modulate cortical excitability, depending mainly
on its amplitude and frequency. PES modulation of cortical excitability is very focal,
occurring only in the stimulated region. The combination of these two neuromodulatory
techniques has showed additive effects in some studies with individuals suffering from
chronic pain,which promoting a general effect (tDCS), and the other a more focal effect
(TENS). Although this additive effect has been demonstrated, to date, no study evaluate its
safety and efficacy in individuals with DF.
As a secondary outcome, the investigators are going to access the influence of the
intervention on quantitative electroencephalography (qEEG). Growing evidence points out to
different brain characteristics between individuals with chronic pain and healthy. qEEG has
high temporal resolution and evaluates primary electrical effects of neural excitation,
allowing identify possible patterns of brain functioning in individuals with chronic pain.
qEEG allowed the identification of the thalamocortical dysrhythmia (TCD) in patients with
chronic pain characterized by an increased low frequency band power density theta (4 - 7Hz)
and a decrease in high frequency bands alpha (8 -12Hz) and beta (13 - 30Hz). This dysrhythmic
mechanism may occur from the periphery to the thalamus (bottom-up) or cortical dysregulation
(top-down), disinhibition of the thalamus. This process results in hyperpolarization of
thalamic neurons, leading to a preponderance of low frequency oscillations in qEEG. The
persistence thalamic firing at low frequencies can lead to a collateral inhibition in
cortical regions around, which could theoretically lead to a decrease in the higher
frequencies. This increase occurs at low frequency regions involved in neuro matrix of pain.
The investigators will alse avaluate the influence of the chronic pain sencondary to
avascular necrosis of hip joint about cortical motor reorganization using transcranial
magnetic stimuation (TMS). Recent data point to a gluteus maximus muscle weakness during
maximal voluntary contraction in pronation position in individuals with joint pain in the
hip. Similarly, individuals with legg calve perthes who suffer from femoral head necrosis,
weakness of the abductor hip musculature was related to poor clinical outcomes. A possible
explanation for these findings is cortical motor reorganization, which is associated with
motor control impairment, and this has been demonstrated in individuals with chronic lateral
epicondylalgia and knee osteoarthritis, where cortical organization is altered and correlated
positively with the time of Pain and is associated with the perpetuation of pain. This
cortical reorganization can occur in the somatotopic areas corresponding to the motor or
sensorial homunculus, having as characteristic an overlap, retraction and "blurring" in the
somatotopic representation of a certain region.
The mediators released by cells of the immune and inflammatory system can act directly on
neurons sensitizing and enabling them (usually peripheral nociceptors or neurons in the
dorsal horn of the spinal cord). There are several mediators in a long and growing list that
includes cytokines and neurotrophins.The major cytokines in an acute inflammation are the
Tumor Necrosis Factor (TNF) and the interleukins (IL-1), IL-6 and IL-8, which are important
mediators of acute and chronic inflammatory reactions, as well as processes of repair and
resolution. High serum levels of IL-8 have been observed in patients in vase-occlusive
crisis, important clinical aspect of the pathogenesis of SCD. The presence of the mutant
allele A appears to influence the expression of the TNF-alpha, being the AA genotype
considered a high producer.
Neurotrophins are dimeric proteins that are essential for the normal development of the
nervous system in vertebrates. This family includes the nerve growth factor (NGF),
brain-derived neurotrophic factor (BDNF) and other neurotrophins (NT). Currently, it is
recognized that certain neurotrophins, particularly the NGF and the brain-derived
neurotrophic factor BDNF play a significant role in nociception, so that the NGF sensitizes
nociceptors at the periphery, while the BDNF enhances the response ability of the dorsal horn
neurons of the spinal cord. The BDNF gene, which encodes the BDNF protein, located on
chromosome 11 at the boundary of regions 11p13 and 11p14 of the human genome has been
investigated in a wide range of areas related to neuroplasticity, including differences in
brain morphology, learning and memory, interactions with brain stimulation protocols of
plasticity induction and recovery after brain injury and has been associated with a wide
variety of neurological disorders, including, for example, depression, schizophrenia and
attention deficit hyperactivity disorder (ADHD).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|